Our Firm is representing a number of individuals who allegedly suffered heart attacks, strokes, and other catastrophic cardiovascular problems related to the 2012 GranuFlo and NaturaLyte recall.
New York, New York (PRWEB) November 17, 2014
GranuFlo and NaturaLyte lawsuits (http://www.granuflolawsuit2014.com/) filed on behalf of patients who were allegedly harmed by the dialysis concentrates continue to mount in federal court, Bernstein Liebhard LLP reports. According to an updated Docket Report issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on November 17th, at least 2,220 claims are now pending in the federal multidistrict litigation now underway in U.S. District Court, District of Massachusetts.* Court records indicate that represents an increase of 73 filings since October 15th, when 2,127 GranuFlo cases were pending. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“Our Firm is representing a number of individuals who allegedly suffered heart attacks, strokes, and other catastrophic cardiovascular problems related to the 2012 GranuFlo and NaturaLyte recall. It is not surprising that the number of cases pending in the federal multidistrict litigation continues to increase, as we continue to hear from other patients who allegedly suffered similar injuries,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who allegedly suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects within 72 hours of a dialysis treatment involving the use of GranuFlo or NaturaLyte dialysis drugs.
GranuFlo and NaturaLyte are dialysis concentrates that are used to remove toxins from the blood of patients suffering from kidney failure. In March 2012, Fresenius Medical Care issued an Urgent Product Notification for both products that warned of dosage issues that could put patients at risk for serious and potentially life-threatening heart side events. The U.S. Food & Drug Administration (FDA) ultimately granted Class I recall status to the Urgent Product Notification, which is the classification used by the agency when a medical product poses a risk of serious injury or death.
Since the GranuFlo recall, court records indicate that thousands of people have filed product liability claims against Fresenius. In addition to the cases pending in the federal multidistrict litigation underway in the District of Massachusetts, additional GranuFlo and NaturaLyte lawsuits have been consolidated on the state level in Massachusetts’ Middlesex County Superior Court. Filings indicate that more than 3,900 claims are pending in that proceeding. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O).
According to court documents, all of the GranuFlo and NaturaLyte lawsuits currently pending in state and federal court were filed on behalf of dialysis patients who allegedly experienced serious cardiovascular events, including heart attacks, strokes, and sudden cardiac death, due to the use of the two products. Among other things, the complaints accuse Fresenius of failing to provide adequate warnings regarding their serious cardiovascular risks. Plaintiffs also assert that the company continued to aggressively market the concentrates even after those dangers became known.
Individuals who were treated with GranuFlo or NaturaLyte prior to the 2012 recall may be eligible for compensation if they suffered a heart attack, stroke or other life-threatening cardiac event within 72 hours of their administration. To learn more about filing a GranuFlo lawsuit, please visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.
*jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-November-17-2014.pdf, JPML, November 17, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP